Background Brain metastases develop in up to 50% patients with metastatic triple negative
breast cancer (TNBC) and HER2+ BC and are an increasing source of morbidity and …

Purpose There is currently no curative treatment for patients diagnosed with triple-negative
breast cancer brain metastases (TNBC-BM). CAR T cells hold potential for curative treatment …

Background: There is an unmet need for evidence-based systemic therapies for pts with
HER2-positive MBC and progressive brain metastases. Despite assumptions that …

BACKGROUND: The PI3K/Akt/mTOR is an important pathway in BCBM. Mutations in
PIK3CA or PTEN loss are associated with trastuzumab resistance. Inhibition of PI3K and …

Simple Summary Results from a previous study suggested that the number of circulating
tumor cells (CTC) might have a role as a biomarker of early distant brain failure in patients …

The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus
high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with …

Background Intracranial metastatic disease (IMD) is a serious and known complication of
human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The role of …

We read with great interest the findings by Lewis-Phillips et al. on the preclinical delivery of
trastuzumab in brain metastases [1]. The authors compared directly the uptake of …

Background: BM in HER2-positive BC patients are increasing, without agreement on the
appropriate treatment of this subgroup. The disrupted blood-brain barrier in the setting of BM …

Purpose: Metastasis to the brain from breast cancer remains a significant clinical challenge,
and may be targeted with CAR-based immunotherapy. CAR design optimization for solid …